Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA


News provided by

The Genesis Prize Foundation

19 Jan, 2022, 20:33 GMT

Share this article

Share toX

Share this article

Share toX

Genesis Prize Chairman highlights immense role of Jewish scientists and doctors in combatting the pandemic: "A very proud moment for the entire Jewish community"

JERUSALEM, Jan. 19, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr. Albert Bourla, Chairman and CEO of Pfizer, as the 2022 Genesis Prize Laureate. Dr. Bourla received the largest number of votes in a recently concluded global campaign, during which 200,000 people in 71 countries voted online. The choice of the voters was unanimously endorsed by the nine judges on the Genesis Prize Selection Committee.

Continue Reading
This image opens in the lightbox
Dr. Albert Bourla. Credit: Joshua Jordan

The Committee commended Dr. Bourla for his leadership, determination, and especially for his willingness to assume great risks. Unlike CEOs of most other major companies working on developing COVID-19 vaccines, Dr. Bourla declined billions of dollars in US federal subsidies in order to avoid government bureaucracy and expedite development and production of the vaccine. As a result, Pfizer's COVID-19 vaccine was ready in record time: months instead of years. 

The annual $1 million Genesis Prize, dubbed the "Jewish Nobel" by TIME Magazine, honors extraordinary individuals for their outstanding professional achievement, contribution to humanity, and commitment to Jewish values. Dr. Bourla becomes the ninth Genesis Prize Laureate. He follows filmmaker and philanthropist Steven Spielberg, who was awarded the Genesis Prize in 2021, and the legendary human rights activist Natan Sharansky, the 2020 Laureate.

The President of Israel Isaac Herzog will present the Genesis Prize to Dr. Bourla at a ceremony in Jerusalem planned for June 29.

In line with the tradition established by the inaugural Laureate Michael Bloomberg, all Genesis Prize honorees have chosen to forgo the monetary award to philanthropic causes.  Dr. Bourla has asked The Genesis Prize Foundation to direct his $1 million prize award to projects aimed at preserving the memory of the victims of the Holocaust, with a particular emphasis on the tragedy suffered by the Greek Jewish community.

Born in Thessaloniki, Greece, Dr. Bourla was raised in a family that knew the horrors of the Holocaust first-hand. His parents were among only 2,000 survivors out of a once-thriving, ancient Jewish community of 50,000, almost completely wiped out by the Nazis.

"I am delighted to welcome Dr. Albert Bourla to the distinguished family of Genesis Prize Laureates," said Co-Founder and Chairman of The Genesis Prize Foundation Stan Polovets. "Dr. Bourla personifies two of the most fundamental Jewish values: the commitment to the sanctity of life and to repairing the world.  And while the pandemic is far from over, millions of people are alive and healthy because of what Dr. Bourla and his team at Pfizer have accomplished."

Dr. Albert Bourla said: "I did not set out to live a public life, and I never could have imagined that I might one day receive the profound honor of the Genesis Prize and stand alongside my extraordinary fellow nominees. I accept it humbly and on behalf of all my Pfizer colleagues who answered the urgent call of history these past two years and together bent the arc of our common destiny. I was brought up in a Jewish family who believed that each of us is only as strong as the bonds of our community; and that we are all called upon by God to repair the world. I look forward to being in Jerusalem to accept this honor in person, which symbolizes the triumph of science and a great hope for our future."

In announcing the selection of Dr. Bourla, The Genesis Prize Foundation noted the wide-ranging contribution of numerous Jewish scientists, doctors, and healthcare officials in helping to save lives during the COVID-19 pandemic. The Foundation specifically highlighted the contributions of the following individuals:

  • Dr. Drew Weissman, Professor of Vaccine Research at the University of Pennsylvania, whose discovery of a novel nucleoside-modified mRNA platform enabled the creation of pioneering mRNA vaccines;
  • Dr. Mikael Dolsten, Chief Scientific Officer, Pfizer, who guided the development of the Pfizer vaccine in record time;
  • Dr. Tal Zaks, Chief Medical Officer of Moderna during the development of the successful mRNA 1273 vaccine;
  • Dr. Joanne Waldstreicher, Chief Medical Officer of Johnson & Johnson, which delivered a successful COVID-19 vector vaccine;
  • Academician Alexander Gintsburg, Director, Gamaleya Institute for Epidemiology and Microbiology, which developed the Sputnik vaccine;
  • Dr. Anatoly Altstein, Chief Scientist, Gamaleya Institute for Epidemiology and Microbiology, who led the development of the Sputnik vaccine;
  • Dr. Rochelle Walensky, Director, US Centers for Disease Control and Prevention, which coordinates the US public health response to the pandemic;
  • Jeffrey Zients, the White House Coronavirus Response Coordinator, who oversees the US federal government response to the pandemic, including vaccine distribution.

Genesis Prize Chairman Stan Polovets said: "This is a very proud moment, not just for Dr. Bourla, but for the entire Jewish community. A people so small in number are having such an outsized impact on this global effort to save lives."

Polovets added: "Dr. Bourla is a bright star in the constellation of outstanding Jewish scientists and doctors at the forefront of fighting the pandemic. We hope that these extraordinary individuals, and their colleagues, join us in Jerusalem to further unite in our common resolve to save lives and honor our heritage."

BACKGROUND

The Genesis Prize is a global award that celebrates Jewish achievement and contribution to humanity. Launched in 2013, the Prize is financed through a permanent endowment of $100 million established by The Genesis Prize Foundation.

Previous Genesis Prize laureates are former New York City Mayor and philanthropist Michael Bloomberg (2014); actor, producer and peace activist Michael Douglas (2015); Itzhak Perlman, virtuoso violinist and advocate for individuals with special needs (2016); sculptor and advocate for the rights of refugees Sir Anish Kapoor (2017); Oscar-winning actress and social activist Natalie Portman (2018); owner of New England Patriots and founder of a new foundation to combat antisemitism Robert Kraft (2019); legendary Jewish leader and human rights activist Natan Sharansky (2020) and filmmaker Steven Spielberg (2021). In 2018, The Genesis Prize Foundation honored U.S. Supreme Court Justice Ruth Bader Ginsburg with its inaugural Lifetime Achievement Award for her contribution to social justice and equal rights. In 2021, the late Rabbi Lord Jonathan Sacks was honored with a posthumous Lifetime Achievement Award in recognition of his illustrious life-long work as a teacher of Jewish values and proponent of inter-religious and intercultural dialogue. 

All previous Laureates have re-gifted their monetary awards to philanthropic causes about which they are passionate. Since inception, The Genesis Prize has leveraged the annual $1 million award into philanthropic initiatives totaling $45 million, with grants going to 197 nonprofit programs in 31 countries, directly impacting the lives of tens of thousands of people. 

Photo - https://mma.prnewswire.com/media/1729874/Dr_Albert_Bourla.jpg

Modal title

Also from this source

Argentina's President Javier Milei Wins the 2025 "Jewish Nobel Prize"

Today, The Genesis Prize announces President of Argentina Javier Milei as the 2025 Genesis Prize Laureate, the first time the award, known as "The...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Infection Control

Infection Control

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.